906371-78-6

Basic information

• Product Name: ethyl 4-(2-chloropyridin-3-ylaMino)piperidine-1-carboxylate
• Synonyms: ethyl 4-(2-chloropyridin-3-ylaMino)piperidine-1-carboxylate
• CAS NO: 906371-78-6
• Molecular Formula: C₁₃H₁₈ClN₃O₂
• Molecular Weight: 283.75392
• Mol File: 906371-78-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 434.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.279±0.06 g/cm3(Predicted)
• PKA: 1.93±0.10(Predicted)
• CAS DataBase Reference: ethyl 4-(2-chloropyridin-3-ylaMino)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-chloropyridin-3-ylaMino)piperidine-1-carboxylate(906371-78-6)
• EPA Substance Registry System: ethyl 4-(2-chloropyridin-3-ylaMino)piperidine-1-carboxylate(906371-78-6)

Safety Data

• Hazardous Substances Data: 906371-78-6(Hazardous Substances Data)

Usage

General Description

Ethyl 4-(2-chloropyridin-3-ylamino)piperidine-1-carboxylate is a chemical compound with the molecular formula C14H19ClN4O2. It is a derivative of piperidine, a heterocyclic organic compound commonly used in pharmaceuticals. The presence of a chloropyridine group in the structure suggests that this compound may have potential applications in medicinal chemistry, particularly in the development of pharmaceuticals targeting specific biological pathways or receptors. The ethyl ester group also indicates that this compound may have some solubility in organic solvents, making it a versatile building block for the synthesis of more complex molecules. More research and analysis would be required to fully understand the potential uses and properties of ethyl 4-(2-chloropyridin-3-ylamino)piperidine-1-carboxylate.

Upstream product

• 906532-72-7 4-[1-(2-chloro-pyridin-3-yl)ureido]piperidine-1-carboxylic acid ethyl ester 
• 6298-19-7 2-chloro-3-aminopyridine 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 

Relevant articles and documents

NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.

PROCESS FOR THE PREPARATION OF PYRIDINE HETEROCYCLE CGRP ANTAGONIST INTERMEDIATE

An efficient syntheses for the preparation of the intermediate 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride, and other salt forms of 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine.

PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST

An efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine -1-carboxamide, by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1''-carbonyldiimidazole (""CDI"") as carbonyl source; and an efficient preparation of the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine -1-carboxamide.